Adam Woodrow has been President and Chief Commercial Officer since June 2019. Prior to that, he served as Chief Commercial Officer between October 2014 and June 2019.
Mr. Woodrow previously worked for Pfizer for five years in various strategic and operational commercial roles. While at Pfizer, he led the commercial development group in Pfizer's Specialty Care Business Unit, launching Xeljanz® for Rheumatoid Arthritis and Vyndaqel® for the treatment of Transthyretin Familial Amyloid Polyneuropathy (TTR-FAP). In addition, he led the global strategic marketing teams for a variety of products in fields ranging from rare disease to acute hospital based infections; major products included Enbrel®, Zyvox®, ReFacto® and Benefix®.
Mr. Woodrow joined Pfizer from Wyeth Pharmaceuticals, where he was Vice President and Global Business Manager for Enbrel leading all commercial aspects of Wyeth's inflammation portfolio, co-promotion, licensing, and product development. In his 10 years at Wyeth, he held senior marketing and sales positions in the US and in his native UK. He was responsible for the successful launches of medicines in the fields of anti-infectives (Tygacil®), hemophilia (ReFacto), primary immune deficiency and women's health. Before joining Wyeth, he held sales and marketing positions with Bayer Pharmaceuticals.
Education & Accomplishments
Mr. Woodrow has a Bachelor of Science degree in Industrial Chemistry from the University of Wales College of Cardiff. During his career in the pharmaceutical industry, he worked with several non-profit societies and organizations.
Passion, accountability, and collaboration. At Paratek, we count on each other to build a company that saves lives. Learn more about life @Paratek.Explore Careers